Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 1
1991 2
1992 1
1993 1
1994 1
1996 3
1997 2
1999 2
2000 5
2001 3
2002 5
2003 4
2004 6
2005 7
2006 5
2007 2
2008 5
2009 7
2010 8
2011 8
2012 5
2013 11
2014 4
2015 7
2016 3
2017 5
2018 9
2019 4
2020 5
2021 3
2022 16
2023 6
2024 6
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Berdeja JG, et al. Among authors: yeh tm. Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24. Lancet. 2021. PMID: 34175021 Clinical Trial.
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. San-Miguel J, et al. Among authors: yeh tm. N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272512 Clinical Trial.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Martin T, et al. Among authors: yeh tm. J Clin Oncol. 2023 Feb 20;41(6):1265-1274. doi: 10.1200/JCO.22.00842. Epub 2022 Jun 4. J Clin Oncol. 2023. PMID: 35658469 Free PMC article.
Autoimmunity in dengue pathogenesis.
Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ling P, Anderson R, Lei HY, Lin YS. Wan SW, et al. Among authors: yeh tm. J Formos Med Assoc. 2013 Jan;112(1):3-11. doi: 10.1016/j.jfma.2012.11.006. Epub 2012 Dec 12. J Formos Med Assoc. 2013. PMID: 23332423 Free article. Review.
Current progress in dengue vaccines.
Wan SW, Lin CF, Wang S, Chen YH, Yeh TM, Liu HS, Anderson R, Lin YS. Wan SW, et al. Among authors: yeh tm. J Biomed Sci. 2013 Jun 13;20(1):37. doi: 10.1186/1423-0127-20-37. J Biomed Sci. 2013. PMID: 23758699 Free PMC article. Review.
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Weisel K, Krishnan A, Schecter JM, Vogel M, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Yalniz F, Nesheiwat T, Van Sanden S, Diels J, Valluri S, Usmani SZ, Berdeja JG, Jagannath S, Martin T. Weisel K, et al. Among authors: yeh tm. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):690-701. doi: 10.1016/j.clml.2022.04.025. Epub 2022 May 23. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35764490 Free article. Clinical Trial.
Immunopathogenesis of dengue virus infection.
Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Lei HY, et al. Among authors: yeh tm. J Biomed Sci. 2001 Sep;8(5):377-88. doi: 10.1007/BF02255946. J Biomed Sci. 2001. PMID: 11549879 Review.
153 results